LCP
OCUL icon

Lamond Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

Lamond Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,233,285
Closed -$17.3M – 11
2015
Q3 		$17.3M Buy
1,233,285
+521,752
+73% +$10.5M 12.98% 3
2015
Q2 		$15M Buy
711,533
+291,290
+69% +$7.22M 15.19% 1
2015
Q1 		$17.6M Buy
420,243
+345,863
+465% +$11.4M 19.28% 1
2014
Q4 		$1.75M Buy
+74,380
New +$1.25M 1.15% 14

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Lamond Capital Partners's OCUL Position: Q4 2015 in Review

Lamond Capital Partners sold out of Ocular Therapeutix (OCUL) in Q4 2015, closing a stake of 1,233,285 shares — an estimated $17.3M sold.

Lamond Capital Partners first reported a position in OCUL in Q4 2014 and held it in 4 quarters. The position peaked at $17.6M in Q1 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q4 2015.

  • Lamond Capital Partners reported no remaining Ocular Therapeutix position as of Q4 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 1,233,285 Ocular Therapeutix shares in Q4 2015, an estimated $17.3M.
  • Lamond Capital Partners first reported a position in Ocular Therapeutix in Q4 2014 and held it in 4 quarters.
  • Lamond Capital Partners's Ocular Therapeutix position peaked at $17.6M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2015.

Based on Lamond Capital Partners's 13F filing for Q4 2015, filed 9 Feb 2016.